# Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

> **NCT06298968** · PHASE2 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 38 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab

## Key facts

- **NCT ID:** NCT06298968
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2025-02-25
- **Final completion:** 2027-02-25
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298968, "Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06298968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*